BioNTech outlines 2026 strategy at J.P. Morgan event

BioNTech SE submitted a report describing a strategic business update delivered at the 44th Annual J.P.

Accepted by SEC EDGAR 01/13/2026 - 06:18 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

BioNTech SE submitted a report describing a strategic business update delivered at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. On January 13, 2026, the company outlined its focus areas for 2026 and provided an overview of expected near- to longer-term milestones. The related presentation is made available as Exhibit 99.1 to this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioNTech SE (BNTX) report in this Form 6-K?

BioNTech SE reported that it provided a strategic business update on January 13, 2026, outlining focus areas for 2026 and expected near- to longer-term milestones at the 44th Annual J.P. Morgan Healthcare Conference.

Where did BioNTech SE present its 2026 strategic business update?

BioNTech SE presented its 2026 strategic business update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

What time frame does BioNTech SE’s update in this report cover?

The update highlights BioNTech SE’s focus areas for 2026 and includes an overview of expected near- to longer-term milestones.

Does this BioNTech SE (BNTX) report include the full presentation?

The report states that the presentation used for the strategic business update is attached as Exhibit 99.1, identified simply as a “Presentation.”

Who signed this BioNTech SE (BNTX) report?

The report was signed on behalf of BioNTech SE by Chief Financial Officer Ramon Zapata-Gomez and Chief Operating Officer Dr. Sierk Poetting.

Is this BioNTech SE (BNTX) report part of its annual reporting?

The document notes that BioNTech SE files its annual reports under cover of Form 20-F, while this document itself is a separate report of a foreign private issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF JANUARY 2026

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On January 13, 2026, BioNTech SE provided a strategic business update and outlined the Company’s focus areas for 2026, including an overview of expected near- to longer-term milestones, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation is attached hereto as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By:

/s/ Ramon Zapata-Gomez

By:

/s/ Dr. Sierk Poetting

Name: Ramon Zapata-Gomez

Name: Dr. Sierk Poetting

Title: Chief Financial Officer

Title: Chief Operating Officer

Date: January 13, 2026

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Presentation